UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
Trump Unveils $3 Billion U.S. Critical Minerals Push 
US Dollar Gains as Iran Tensions, Fed Rate Hike Bets Rise 
US Dollar Falls as Weak July Jobs Report Dents Fed Rate Hike Bets 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Australia Trade Surplus Returns in June as Iron Ore, Coal and LNG Exports Surge 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
China Exports Beat July Forecasts as AI Demand Fuels High-Tech Trade 
Brazil Cuts Selic Rate to 14% as Inflation Eases but Risks Persist 
Philippine GDP Growth Slows to 2.3% in Q2 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Celltrion, the South Korean pharmaceutical company, revealed that it had sealed its first deal for shipments of its Rekirona COVID-19 antibody treatment. The firm made the announcement on the supply transaction to Pakistan on Monday, May 10.
Celltrion’s Healthcare division will be managing its overseas business, so it was the company affiliate that signed the deal with Pakistan’s state-run company. The first order is for the shipment of 100,000 vials of Rekirona, which is enough for 30,000 people.
Rekirona receives approval from S. Korea’s drug safety board
As per The Korea Herald, once the vials of the COVID-19 antibody treatment have been delivered, Celltrion will also send its experts to Pakistan so they can train the local medical healthcare providers who have been assigned to administer the treatment.
In February, Celltrion’s Rekirona already received conditional approval from the drug safety board in S. Korea. With that, the medication effectively became the first locally-made treatment for coronavirus.
The treatment has been given to around 2,700 high-risk patients, which include individuals who are over 60 years of age. People with chronic diseases that affect the respiratory system were also administered with Rekirona earlier this year, and the results seem promising, or it will not be approved.
Celltrion already completed the third phase of clinical trials that was conducted in 13 countries with 1,300 volunteers. Aside from S. Korea, some of these nations are the U.S. and Spain. Now, the pharma company is hoping that its Rekirona will be able to help stop the growing number of patients in Pakistan.
Celltrion starts global rollout of its COVID-19 treatment
Yonhap News Agency reported that it is not just Pakistan that will have Celltrion’s Rekirona as there are also ongoing negotiations for supply to Europe, U.S., and more. The exports will start in Pakistan, and the distribution will eventually spread to other nations.
"Talks are also currently underway to export Rekirona to other countries in Europe and South America, as well as India," an official from Celltrion said. Meanwhile, two other pharmaceutical companies are developing similar monoclonal antibody treatment, and these are the US-based Regeneron and Eli Lilly. These are still under clinical tests, so it makes Celltrion the first to make a COVID-19 treatment available globally.
